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COVID-19 in a patient with systemic sclerosis 
treated with tocilizumab for SSc- ILD
During the current global outbreak of coronavirus disease 2019 
(COVID-19), risk stratification of patients is of utmost importance. 
Currently, patients >65 years and those with pre- existing medical 
conditions such as cardiovascular disease, chronic respiratory 
disease or diabetes mellitus are considered at higher risk for severe 
disease.1 The Swiss Federal Office of Public Health, like similar 
authorities around the world, has additionally included patients on 
immunosuppressants in the high- risk group for developing severe 
COVID-19.2 However, at this moment we do not have enough 
evidence either to support or to reject this assumption.
We report the case of a 57- year- old woman with systemic scle-
rosis (SSc) who developed COVID-19. Comorbidities were insulin- 
dependent type 2 diabetes mellitus and WHO grade I obesity. The 
anti- topoisomerase I antibody- positive patient was diagnosed with 
SSc in 2017. SSc- associated interstitial lung disease (SSc- ILD), with 
cough and exertion dyspnoea, was the leading organ manifesta-
tion, associated with symmetrical, non- erosive polyarthritis, and 
elevated acute phase reactants. Treatment with the anti- interleukin 
(IL) 6 receptor blocker tocilizumab, with 8 mg/kg body weight 
every 4 weeks intravenously, was started, leading to a good control 
of both arthritis and SSc- ILD, with gradual improvement of muscu-
loskeletal and respiratory symptoms, lung function and high- 
resolution CT imaging (figure 1). At the last annual assessment in 
January 2020, her forced vital capacity and carbon monoxide lung 
diffusion capacity were 92% and 70% of the respective predicted 
values. Tocilizumab was continued at 5- week intervals.
On 12 March 2020, 4 weeks after the last tocilizumab infusion, 
the patient presented to our hospital’s emergency department 
with cough, headache and general malaise since about 1 week. She 
reported contact with a patient with COVID-19 2 weeks earlier. 
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Figure 1 High- resolution CT (HRCT) of the chest, 8 weeks before 
onset of coronavirus disease 2019 (COVID-19). Ground glass and 
reticulation as signs of systemic sclerosis (SSc)- associated interstitial 
lung disease are visible, with an overall lung involvement of <20%.
(37.6°C), with unchanged bibasal lung crackles and no significant 
dyspnoea, she was allowed to return home with symptomatic treat-
ment only. The nasopharyngeal swab was positive for the Severe 
Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV2) by real- 
time reverse transcription- PCR. She was quarantined at home and 
monitored by daily telephone calls, and the upcoming tocilizumab 
infusion was postponed. The symptoms remained mild, and, 10 
days later, she reported to be free of symptoms. A follow- up naso-
pharyngeal swab for SARS- Cov2 performed on March 26 turned 
out negative. She was thus declared cured from the infection and 
scheduled to receive the next tocilizumab dose 4 days after the 
negative test.
In this case, a patient with insulin- dependent type 2 diabetes 
mellitus and SSc- ILD treated with tocilizumab developed a mild 
form of COVID-19. Her pre- existing ILD and diabetes are WHO- 
defined risk factors for a more severe course of COVID-19,1 while 
immunosuppressive treatment is currently also regarded as a risk 
factor.2 In previous coronavirus outbreaks however, immunosup-
pression was not a documented risk factor.3 At present, in patients 
with COVID-19 from Wuhan, China, higher levels of C reactive 
protein and IL-6 have been associated with increased mortality.4 
Accumulating evidence suggests that a subgroup of patients with 
severe COVID-19 develop a cytokine storm syndrome.4 Currently, 
several ongoing randomised trials study the efficacy and safety of 
anti- IL-6- receptor monoclonal antibodies in severe COVID-19.5 6 
Although these agents are immunosuppressive and thus formally 
contraindicated in patients with active infections, they may show 
benefit in certain subgroups of COVID-19- associated severe acute 
respiratory distress syndrome. In addition, our case indicates that 
IL-6- blocking treatment given for chronic autoimmune diseases 
such as rheumatoid arthritis or connective tissue disease may even 
prevent the development of severe COVID-19. While we are 
fully aware of the limitations of single- case observations, we think 
the presented case report supports this hypothesis. Thus, future 
prospective, controlled studies should include an analysis for the 
potential preventive effects of IL-6 blockade in COVID-19.
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